

DOWNSTATE HEALTH SCIENCES UNIVERSITY/UNIVERSITY HOSPITAL AT DOWNSTATE
POLICY AND PROCEDURE

No. PTSAF-19

Subject: Adult Therapeutic Heparin and
Enoxaparin Guideline Anticoagulation

Page: 1 of 11

Prepared by: Manisa Tanprayoon, PharmD

Original Issue Date: 12/2019

Supersedes: 12/2025

Effective Date: 1/2026

Committee Approval:
Medication Safety Committee
Pharmacy and Therapeutics Committee
Medical Executive Committee
Executive Performance Improvement Council (EPIC)

TJC Standards:

MM.01.01.03: The organization safely manages high-alert and hazardous medications.

NPSG.03.05.01: Reduce the likelihood of patient harm associated with the use of anticoagulant therapy.

Issued by: Regulatory Affairs

I. PURPOSE

This document provides guidance to clinicians regarding the safe and effective utilization of unfractionated heparin and low molecular weight heparin in adult patients at the Downstate Health Sciences University/University Hospital at Downstate.

Anticoagulant agents, such as heparin and enoxaparin, are identified as high-risk medications by the Institute for Safe Medication Practices and the Downstate Health Sciences University. They possess the potential for serious patient harm if used in error.

II. POLICY

Treatment with heparin and enoxaparin will follow the standardized prescribing, administration, and monitoring guidelines as outlined in this document. Patient-specific deviations shall be discussed on a case-by-case basis, and treatment will be individualized as needed by responsible providers with appropriate education and monitoring.

PTSAF-19: Adult Therapeutic Heparin and Enoxaparin Guideline Anticoagulation

Recommendations should not preclude clinical judgment. Contact the pharmacy with any questions or for further assistance.

III. DEFINITION(s)

1. Anticoagulation: Pharmacologic therapy that will alter a patient's coagulation cascade, which will ultimately impair a patient's ability to form fibrin clots. A therapeutically anticoagulated patient will also be at a higher risk of experiencing a hemorrhage.
2. Reversal of Anticoagulation: The process of administering a pharmacologic reversal agent or blood product to effectively restore an anticoagulated patient's coagulation cascade.

IV. RESPONSIBILITIES

Pharmacy

V. PROCEDURES/GUIDELINES

A. THERAPEUTIC UNFRACTIONATED HEPARIN

1. Therapeutic IV heparin Prescribing:
 - a. Downstate Health Sciences University recognizes the following approved protocols in adult patients (see Appendix A & B):
 - i. Heparin Protocol for Adult Patients
 - ii. Transitioning to and from Enoxaparin (LMWH) or Unfractionated Heparin (UFH)
 - b. Prescribers shall order and review aPTT and CBC prior to initiation or renewal of heparin continuous infusion orders. Further work-up of abnormal anticoagulation results should be considered prior to the initiation of anticoagulation therapy, whenever possible. Consult Hematology for recommendations, if needed.
 - c. Providers shall utilize an order set in the electronic medical record to prescribe heparin for adult patients, which includes:
 - i. Order for the heparin continuous infusion for initial treatment based on the indication and maintenance treatment based on the patient location.
 - ii. Order for heparin infusion shall be written for no more than 24 hours. Prescribers must renew the order on daily basis if the patient requires further treatment.
 - iii. Orders for nurses to notify providers during specific situations or occurrences

PTSAF-19: Adult Therapeutic Heparin and Enoxaparin Guideline Anticoagulation

- d. Prior to prescribing and order verification, providers and pharmacists will verify that there is a baseline aPTT and no current aPTT >90 seconds, as well as any contraindications.
 - e. To determine how to transition to and from unfractionated heparin, see Appendix B.
2. **Therapeutic IV Heparin Administration and Monitoring**
- a. Prior to the initiation of an IV heparin infusion, and with each bag change or rate adjustment, there shall be an independent double-check of the drug name, product strength and concentration, dose and rate calculation, pump setting, and patient identity using at least two identifiers
 - b. Prior to administration, nurses will verify that there is no current aPTT >90 seconds
 - c. At **6 hours** after initiation or rate adjustment of the IV heparin infusion, a STAT aPTT shall be collected in a blue-top sodium citrate tube and sent immediately
 - i. **In intensive care units** (except the pediatric intensive care unit and the emergency department), nurses shall adjust heparin rates according to aPTT results as per the nomogram (see Appendix A). Nurses shall contact providers if there are any questions or uncertainties.
 - ii. **In non-intensive care unit settings**, nurses shall notify the providers of the time of the aPTT blood draw to facilitate timely follow-up of results. Providers are responsible for entering a new order if a rate adjustment is needed.
 - d. Ongoing monitoring of IV heparin therapy includes:
 - i. Daily CBC, or more often at the prescriber's discretion
 - ii. aPTT should be checked **6 hours** after any heparin rate adjustment until two consecutive aPTT values are within the therapeutic range. Thereafter, aPTT should be checked at least once daily or more often at the prescriber's discretion.

B. THERAPEUTIC ENOXAPARIN

1. **Therapeutic Enoxaparin Prescribing:** Providers will enter enoxaparin orders with a discrete dose (in mg) and frequency
- a. Ensure a CBC and serum creatinine for baseline evaluation are available prior to or upon initiation of enoxaparin.
 - b. For *therapeutic* anticoagulation, use actual body weight in most cases. Special populations may warrant additional considerations based on clinical judgment.
 - c. All mg/kg doses should be rounded based on Therapeutic Enoxaparin Dose Rounding Guidelines (**Table 2**).
 - i. Pharmacist will round the ordered doses based on the approved guidelines.

PTSAF-19: Adult Therapeutic Heparin and Enoxaparin Guideline Anticoagulation

Table 1. Therapeutic Enoxaparin Dosing and Considerations

Indication	Standard Dose	Special Populations and Considerations
Therapeutic Anticoagulation	1 mg/kg q12h <u>or</u> 1.5 mg/kg q24h [Actual body weight used in most cases]	<p><u>CrCl <30 mL/min:</u></p> <ul style="list-style-type: none"> Dosage adjustment warranted (1 mg/kg q24h) Recommend checking anti-Xa to confirm dosing strategy* <p><u>End-stage renal disease or acute renal failure:</u></p> <ul style="list-style-type: none"> Consider an alternative anticoagulant if possible <p><u>Elderly patients with borderline renal function:</u></p> <ul style="list-style-type: none"> Consider utilizing a lower weight-based dose (example: 0.75 mg/kg q12h) to avoid excessive anticoagulation Recommend checking anti-Xa to confirm dosing strategy* <p><u>Obese patients:</u></p> <ul style="list-style-type: none"> BMI ≥ 40 kg/m² and/or weight ≥ 150 kg: Enoxaparin 0.75 mg/kg q12h Weight ≥ 150 kg: Enoxaparin 0.75 mg/kg q12h and consider anti-Xa monitoring Avoid once daily dosing Dose capping based on weight is not recommended. Recommend checking anti-Xa to confirm dosing strategy* <p><u>Low-weight patients</u></p> <ul style="list-style-type: none"> Weight-based dosing in patients less than 50 kg is not encouraged Recommend checking anti-Xa to confirm dosing strategy*

Note: *Anti-Xa may be elevated with recent use of direct factor Xa inhibitors (apixaban, rivaroxaban).
Ensure appropriate timing when transitioning to and from anticoagulant agents.

Table 2. Therapeutic Enoxaparin Dose Rounding Guidelines

Dose Written (mg)	Rounded Dose (mg)	Syringes Dispensed
25 - 34	30 (0.3 mL)	30 mg x 1
35 - 49	40 (0.4 mL)	40 mg x 1
50 - 69	60 (0.6 mL)	60 mg x 1
70 - 89	80 (0.8 mL)	80 mg x 1
90 - 109	100 (1 mL)	100 mg x 1
110 - 134	120 (0.8 mL)	120 mg x 1
135 - 164	150 (1 mL)	150 mg x 1
Dose capping based on weight is not recommended. Doses <25 mg and >164 mg will be prepared as patient-specific syringes by the pharmacy, rounded to the nearest 10 mg.		

2. To determine how to transition to and from enoxaparin, see Appendix B.
3. Enoxaparin use with neuraxial anesthesia is not recommended due to the risk of developing a spinal hematoma. Consider an alternative anticoagulant if possible.
 - a. If the patient is on therapeutic enoxaparin, hold the dose of enoxaparin for at least 24 hours prior to inserting a spinal/epidural needle/catheter.
 - i. If the patient is on prophylactic enoxaparin, hold a dose of enoxaparin for at least 12 hours prior to inserting a spinal/epidural needle/catheter.

PTSAF-19: Adult Therapeutic Heparin and Enoxaparin Guideline Anticoagulation

- ii. Do not start/restart enoxaparin for at least 2 hours after removal of the catheter/needle.
 - b. In spinal surgery patients, do not start *prophylactic* enoxaparin until the indwelling epidural catheter has been removed for at least 24 hours
4. **Therapeutic Enoxaparin Monitoring**
- a. Anti-Xa peak monitoring is not routinely recommended for all patients receiving enoxaparin but may be considered in patients with the following characteristics:
 - i. Severe renal impairment or fluctuating renal function
 - ii. Elderly patients with borderline renal function and/or higher risk of bleeding
 - iii. Obesity (>150 kg) or low-weight (<45 kg)
 - iv. Patients with coagulation disorders at higher thrombotic risk
 - v. Pregnant patients on long-term therapy
 - vi. Pediatric patients on long-term therapy
 - b. Goal anti-Xa peak for *therapeutic* enoxaparin
 - i. 0.5 to 1 unit/mL for twice-daily dosing
 - ii. 1 to 2 units/mL for once-daily dosing
 - c. Anti-Xa peak should be drawn 4 hours after the 3rd or 4th enoxaparin dose is administered. Dose adjustments may be made based on the anti-Xa results.

Table 2. Anti-Xa Monitoring and Dose Adjustment Recommendations for Therapeutic Enoxaparin

Anti-Xa (unit/mL)	Dose Adjustment*	Time to Repeat Anti-Xa*
<0.35	Increase dose by 25%	4 hours after the next dose
0.35 – 0.49	Increase dose by 10%	4 hours after the next dose
0.5 – 1	No change	At the prescriber's discretion
1.1 – 1.5	Hold the next dose for 3 hours, and decrease the dose by 20%	4 hours after the next dose
1.6 – 2	Hold the next dose for 6 hours, and decrease the dose by 30%	4 hours after the next dose
>2	Hold dose until anti-Xa level ≤0.5 unit/mL (Check anti-Xa q12h), then decrease dose by 40%	4 hours after the next dose

Note: *Recommendations should not preclude clinical judgment. Contact Pharmacy for any uncertainties.

C. PROCEDURES/GUIDELINES FOR REVERSAL OF HEPARIN OR ENOXAPARIN

1. In the setting of a major or life-threatening bleed, discontinue anticoagulation immediately. Protamine sulfate is available for the reversal of heparin or enoxaparin.
 - a. Fully neutralizes the anticoagulant activity of heparin
 - b. Partially neutralizes anti-Xa activity of enoxaparin (up to 75% neutralized)
2. All clinicians should review coagulation results and contraindications prior to ordering, verifying, and administering protamine sulfate.
 - a. The dosing of protamine sulfate is dependent on the anticoagulant received and the timeframe.

Table 3. Protamine Sulfate Dosing

Agent	Protamine Reversal Dose (Maximum 50 mg/dose) *	Laboratory Monitoring[†]
IV Heparin	<ul style="list-style-type: none"> • 1 mg of protamine per 100 units of IV heparin received within the previous 2 – 3 hours • May administer a repeat dose if ongoing bleeding or aPTT remains prolonged 	Obtain baseline aPTT and repeat aPTT 15 minutes after each protamine dose
SC Heparin	<ul style="list-style-type: none"> • 1 mg of protamine per 100 units of SC heparin • May administer 50% of the dose as a bolus over 10 minutes, followed by an infusion of the remaining 50% over 8 – 16 hours 	Obtain baseline aPTT and repeat aPTT 15 minutes after each protamine dose
Enoxaparin	<ul style="list-style-type: none"> • If ≤8 hours ago: 1 mg of protamine per 1 mg of enoxaparin • If >8 hours ago: 0.5 mg of protamine per 1 mg of enoxaparin • May administer a repeat dose if ongoing bleeding or anti-Xa remains elevated 	Obtain baseline anti-Xa and repeat anti-Xa 15 minutes after each protamine dose

Note: **Maximum single dose of protamine should not exceed 50 mg. Excessive protamine doses may paradoxically worsen the bleeding since protamine itself possesses weak anticoagulant activity*

Note: *†Phenomenon of “heparin rebound” may occur up to 18 hours after protamine administration. If there is a concern for re-bleeding, can check aPTT to guide further therapy.*

3. Protamine sulfate doses should be administered IV over a minimum of 10 minutes. Monitor for infusion-related adverse events:
 - a. Hypotension, bradycardia, anaphylactoid reactions, and anaphylaxis
 - b. Rapid administration, fish allergy, or previous exposure to protamine or NPH insulin may increase the risk of developing a reaction

VI. ATTACHMENTS

- A. Appendix A. Adult Heparin Protocols
- B. Appendix B. Transition of Anticoagulants

PTSAF-19: Adult Therapeutic Heparin and Enoxaparin Guideline Anticoagulation

VII. REFERENCES

1. Joint Commission Standards, E-dition, July 2025
2. Lexi-Drugs. Lexicomp Online [database online]. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. <http://online.lexi.com>.
3. Nutescu EA, Dager W. Heparin, low molecular weight heparin, and fondaparinux. In: Gulseth M, ed. Managing Anticoagulation Patients in the Hospital. American Society of Health-System Pharmacists; 2007:181.
4. Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.
5. Curry MA, LaFollette JA, Alexander BR, Evans KS, Tran RH, Kempton CL. Evaluation of treatment-dose enoxaparin in acutely ill morbidly obese patients at an Academic Medical Center: A randomized clinical trial. Ann Pharmacother. 2019;53(6):567-573.
6. Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother. 2018;52(9):898-909.
7. Thompson-Moore NR, Wanat MA, Putney DR, Liebl PH, Chandler WL, Muntz JE. Evaluation and pharmacokinetics of treatment dose enoxaparin in hospitalized patients with morbid obesity. Clin Appl Thromb Hemost. 2015;21(6):513-520.
8. van Oosterom N, Winckel K, Barras M. Evaluation of weight-based enoxaparin dosing on anti-Xa concentrations in patients with obesity. J Thromb Thrombolysis. 2019;48(3):387-393.

DATE REVIEWED	REVISION REQUIRED (CLICK BOX)		RESPONSIBLE STAFF NAME AND TITLE
	YES	NO	
12/2019	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Pharmacy & Therapeutics Committee
03/2022	<input type="checkbox"/>	<input checked="" type="checkbox"/>	Medication Safety Committee, Pharmacy & Therapeutics Committee
07/12/2024	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Medication Safety Committee, Pharmacy & Therapeutics Committee
02/13/2025	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Manisa Tanprayoon, PharmD Sun Hyee Park, PharmD
05/12/2025	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Manisa Tanprayoon, PharmD Medication Safety Committee

PTSAF-19: Adult Therapeutic Heparin and Enoxaparin Guideline Anticoagulation

6/10/2025	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Manisa Tanprayoon, PharmD Medication Safety Committee
10/16/2025	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Teresa Chan, PharmD
11/2025	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Manisa Tanprayoon, PharmD Jisoo Kim, PharmD
1/2026	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Teresa Chan, PharmD

Appendix A. Adult Heparin Protocols at the Downstate Health Sciences University

Disclaimer: This protocol is not meant to substitute professional medical judgment. Clinician may deviate from the protocol to meet the individual patient's specific condition and health care needs.

Heparin Protocols for Adult Patients

Table 1. Initiation of IV Heparin Infusion **For ALL Patient Care Areas******

LOW Dose Protocol: acute coronary syndrome, atrial fibrillation, concomitant thrombolytic therapy, or therapeutic anticoagulation desired but patient is at a high risk of bleeding due to acute condition, previous history of bleeding

Initial Bolus Dose (Optional)	Initial Infusion Dose
60 units/kg - Round to closest 100 units - Maximum bolus dose of 5,000 units - Bolus dose administered over 3 minutes	12 units/kg/hr - Round to closest 50 units/hr - Maximum initial dose 1,000 units/hr - Order defaults to duration of 24 hours

HIGH Dose Protocol: DVT, PE, mechanical valve replacement

Initial Bolus Dose (Optional)	Initial Infusion Dose
80 units/kg - Round to closest 100 units - Maximum bolus dose of 10,000 units - Bolus dose administered over 3 minutes	18 units/kg/hr - Round to closest 50 units/hr. - Maximum <u>initial</u> rate of 2,000 units/hr - Order defaults to a duration of 24 hours

**Table 2. Maintenance Dose Adjustments Based on aPTT Results (Target aPTT 60-80 seconds)
****For Non-Intensive Care Units******

aPTT (sec)	Bolus	Maintenance Infusion Dosage Change	Next aPTT After Change
<45	40 units/kg* <i>*Refer table 3 below for bolus dose adjustment</i>	Increase rate by 3 units/kg/hr	6 hours
45-60	NONE	Increase rate by 2 units/kg/hr	6 hours
60-80 (Goal)	NONE	NO CHANGE	6 hours until therapeutic x 2 consecutive values, then q24h
81-90	NONE	Decrease rate by 3 units/kg/hr	6 hours
> 90	NONE	STOP infusion for 2 hours, Then, decrease rate by 3 units/kg/hr	2 hours after infusion resumed

Table 3. Bolus Dose Adjustment (40 units/kg) **For Non-Intensive Care Units******

Patient Weight (kg)	<60 kg	60-85 kg	85-110 kg	>110 kg
Dose	2,000 units	3,000 units	4,000 units	5,000 units Maximum

Disclaimer: This protocol is not meant to substitute professional medical judgment. Clinician may deviate from the protocol to meet the individual patient's specific condition and health care needs.

Table 4. Maintenance Dose Adjustment Heparin IV Nomogram **For Intensive Care Units
(Target aPTT 60-80 seconds)**

MAINTENANCE IV HEPARIN ORDERS: Adjust IV Dose Based on Subsequent aPTT As Per Table.							
aPTT (sec)	BOLUS (Round to nearest 100 units)	Dosage Change	Dosage Change Based on Weight* (Round Doses to Nearest 50 units/hr)				NEXT aPTT <u>After</u> Change
			40-59 kg	60-69 kg	70-79 kg	>80 kg	
< 35	60 units/kg = ____ units	+ 3 units/kg/hr	↑ by 150 units/hr	↑ by 200 units/hr	↑ by 250 units/hr	↑ by 300 units/hr	6 hours
35-44	30 units/kg = ____ units	+ 2 units/kg/hr	↑ by 100 units/hr	↑ by 150 units/hr	↑ by 150 units/hr	↑ by 200 units/hr	6 hours
45-59	NONE	+ 2 units/kg/hr	↑ by 100 units/hr	↑ by 150 units/hr	↑ by 150 units/hr	↑ by 200 units/hr	6 hours
60-80 (Goal)	NONE	NO CHANGE	NO CHANGE				12 hours
81-95	NONE	- 2 units/kg/hr	↓ by 100 units/hr	↓ by 150 units/hr	↓ by 150 units/hr	↓ by 200 units/hr	6 hours
> 95	NONE	STOP x 1 hour; Restart at - 3 units/kg/hr	↓ by 150 units/hr	↓ by 200 units/hr	↓ by 250 units/hr	↓ by 300 units/hr	6 hours

Appendix B. Transitioning to and from Enoxaparin (LMWH) or Unfractionated Heparin (UFH)

From	To	Action
Apixaban (Eliquis®)	LMWH/UFH	<ul style="list-style-type: none"> Start enoxaparin or heparin infusion when the next apixaban dose would have been due
Dabigatran (Pradaxa®)	LMWH/UFH	<ul style="list-style-type: none"> CrCl ≥30 mL/min: start 12 hours after the last dose of dabigatran CrCl <30 mL/min: start 24 hours after the last dose of dabigatran
Rivaroxaban (Xarelto®)	LMWH/UFH	<ul style="list-style-type: none"> Start enoxaparin or heparin infusion when the next rivaroxaban dose would have been due
Warfarin	LMWH/UFH	<ul style="list-style-type: none"> Start enoxaparin or heparin infusion when INR <2
LMWH (enoxaparin)	Warfarin	<ul style="list-style-type: none"> Start warfarin when clinically indicated If choosing to bridge warfarin with enoxaparin, it may overlap therapy until goal INR achieved
	DOAC*	<ul style="list-style-type: none"> Start DOAC when the next enoxaparin dose would have been due <ul style="list-style-type: none"> - For high-risk thrombotic patients, can consider starting 2 hours before when the next enoxaparin dose would have been due - For high-risk bleeding patients, can consider starting 2 hours after when the next enoxaparin dose would have been due
	UFH	<ul style="list-style-type: none"> Start heparin infusion 1 hour before when the next enoxaparin dose would have been due <ul style="list-style-type: none"> - For high-risk thrombotic patients, can consider starting 2 hours before when the next enoxaparin dose would have been due - For high-risk bleeding patients, can consider starting exactly when the next enoxaparin dose would have been due
UFH Infusion	Warfarin	<ul style="list-style-type: none"> Start warfarin when clinically indicated If choosing to bridge warfarin with heparin infusion, it may overlap therapy until goal INR achieved
	DOAC*	<ul style="list-style-type: none"> Start DOAC at the same time the heparin infusion is stopped
	LMWH	<ul style="list-style-type: none"> Start enoxaparin at the same time the heparin infusion is stopped <ul style="list-style-type: none"> - For high-risk thrombotic patients can consider starting 1 hour before stopping the heparin infusion - For high-risk bleeding, patients can consider starting 1 hour after stopping the heparin infusion

Note: *If already received ≥48 hours of therapeutic LMWH or UFH for treatment of DVT/PE, consider discussing with Hematology and/or Pharmacy regarding the optimal duration of the initial load for apixaban and rivaroxaban. Take into consideration clot burden, thrombotic risk, and bleeding risk of the patient.